MoonLake Immunotherapeutics (MLTX)
10.77
-0.18
(-1.64%)
USD |
NASDAQ |
Oct 07, 16:00
10.81
+0.04
(+0.37%)
After-Hours: 20:00
MoonLake Immunotherapeutics Debt to Equity Ratio : 0.2371 for June 30, 2026
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.2371 |
| March 31, 2026 | 0.3968 |
| December 31, 2025 | 0.2486 |
| September 30, 2025 | 0.2621 |
| June 30, 2025 | 0.2142 |
| March 31, 2025 | 0.1855 |
| December 31, 2024 | 0.0063 |
| September 30, 2024 | 0.0069 |
| June 30, 2024 | 0.0064 |
| March 31, 2024 | 0.0067 |
| December 31, 2023 | 0.0075 |
| September 30, 2023 | 0.0004 |
| Date | Value |
|---|---|
| June 30, 2023 | 0.0004 |
| March 31, 2023 | 0.0059 |
| December 31, 2022 | 0.0058 |
| September 30, 2022 | 0.00 |
| June 30, 2022 | 0.00 |
| March 31, 2022 | 0.621 |
| December 31, 2021 | -1.288 |
| September 30, 2021 | 0.00 |
| June 30, 2021 | 0.00 |
| March 31, 2021 | 0.00 |
| December 31, 2020 | 0.0005 |
| September 30, 2020 | 2.655 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| Basilea Pharmaceutica AG | -- |
| Santhera Pharmaceuticals Holding AG | -- |
| BeOne Medicines Ltd. | 0.3961 |
| AC Immune SA | 0.1166 |
| CRISPR Therapeutics AG | 0.4487 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 573.95M |
| Total Liabilities (Quarterly) | 145.75M |
| Shareholders Equity (Quarterly) | 428.20M |
| Current Ratio | 12.56 |
| Net Debt Paydown Yield | -0.32% |